Last reviewed · How we verify
NCT05646056
A Noninterventional, Single-Center Feasibility Study to Evaluate Measures of Heart Failure Risk
trial testing Software in Heart Failure in 82 participants. Completed in 18 September 2024.
18 September 2024
Quick facts
| Lead sponsor | Prolaio |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 82 |
| Start date | 28 October 2022 |
| Primary completion | 18 September 2024 |
| Estimated completion | 18 September 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Software
Conditions studied
- Heart Failure — all drugs for Heart Failure →
- Cardiomyopathy, Hypertrophic — all drugs for Cardiomyopathy, Hypertrophic →
- Left Ventricular Hypertrophy — all drugs for Left Ventricular Hypertrophy →
Sponsor
Prolaio
Who can join
18 and older, any sex, with Heart Failure or Cardiomyopathy, Hypertrophic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a non-invasive/observational study in healthy and mild HF subjects utilizing clinical and ambulatory measurements to improve detection, monitoring, and management of HF risks.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05646056
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Software
Trials testing the same drug.
- NCT03351374 — Web Platform to Integrate Behavioral Health · unknown
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other Prolaio trials
Trials by the same sponsor.
- NCT05678530 — Observational, Non-Interventional Study Supporting Validation of VO2Max Estimation Methods Using Results in Patients Rec · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05646056 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Prolaio
- Last refreshed: 24 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05646056.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing